



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lambeth et al.

Application No. 10/621,113

Filed: July 16, 2003

Confirmation No. 3341

For: REGULATORY PROTEIN FOR NOX
ENZYMES

Examiner: Tekchand Saidha

Art Unit: 1652

Attorney Reference No. 6975-69498-03

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed May 4, 2005

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.


However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446
cc: Docketing



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6975-69498-03
Application Number	10/621,113
Filing Date	July 16, 2003
First Named Inventor	Lambeth
Art Unit	1652
Examiner Name	Tekchand

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		PCT	WO01/75067	10/11/2001	HYSEQ, Inc.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		CHENG, Guangjie et al., <i>Journal of Biological Chemistry</i> , Vol. 279, No. 6, Feb. 6, 2004, pp. 4737-4742.
		CHENG, Guangjie et al., <i>Journal of Biological Chemistry</i> , Vol. 279, No. 33, Aug. 13, 2004, pp. 34250-34255.
		GEISZT, Miklos et al., <i>Journal of Biological Chemistry</i> , Vol. 278, No. 22, May 30, 2003, pp. 20006-20012.
		TAKEYA, Ryu et al., <i>Journal of Biological Chemistry</i> , Vol. 278, No. 27, July 4, 2003, pp. 25234-25246.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.